TNXP (Tonix Pharmaceuticals Holding) Total Long-Term Assets: $50.74 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TNXP Tonix Pharmaceuticals Holding Corp TNXP
39 GF Score
Price $11.18
GF Value $1.75
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Total Long-Term Assets?

Tonix Pharmaceuticals Holding TNXP +4.88% 39 Total Long-Term Assets is $50.74 Mil as of Mar. 2026. GuruFocus rates TNXP with a GF Score™ of 39/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Tonix Pharmaceuticals Holding's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $50.74 Mil.

Tonix Pharmaceuticals Holding Total Long-Term Assets Related Terms

Tonix Pharmaceuticals Holding Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Tonix Pharmaceuticals Holding's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Total Long-Term Assets Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.85 94.91 106.69 43.89 48.30

Tonix Pharmaceuticals Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.30 43.82 44.37 48.30 50.74
TNXP
39GF Score
Tonix Pharmaceuticals Holding Corp TNXP
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonix Pharmaceuticals Holding Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $50.74 Mil mean?
Tonix Pharmaceuticals Holding (TNXP) has a Total Long-Term Assets of $50.74 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Tonix Pharmaceuticals Holding and its competitors.
Is Tonix Pharmaceuticals Holding's Total Long-Term Assets too high?
Tonix Pharmaceuticals Holding's current Total Long-Term Assets is $50.74 Mil. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Total Long-Term Assets compare to EQ and ARCT?
Tonix Pharmaceuticals Holding's Total Long-Term Assets of $50.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Tonix Pharmaceuticals Holding and its competitors. Tonix Pharmaceuticals Holding's current Total Long-Term Assets is $50.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $11.18 — trading 538.9% above its estimated fair value. The current Total Long-Term Assets is $50.74 Mil. Tonix Pharmaceuticals Holding's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Total Long-Term Assets is $50.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $11.18 is trading 538.9% above its estimated GF Value™ of $1.75. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

  • Total Long-Term Assets: $50.74 Mil
  • GF Value™: $1.75 vs. price of $11.18 (538.9% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonix Pharmaceuticals Holding Business Description

Other Exchanges TPM0:Germany
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
39GF Score

Get the complete analysis for TNXP

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.18
Price
$1.75
GF Value